JP2004529167A5 - - Google Patents

Download PDF

Info

Publication number
JP2004529167A5
JP2004529167A5 JP2002586950A JP2002586950A JP2004529167A5 JP 2004529167 A5 JP2004529167 A5 JP 2004529167A5 JP 2002586950 A JP2002586950 A JP 2002586950A JP 2002586950 A JP2002586950 A JP 2002586950A JP 2004529167 A5 JP2004529167 A5 JP 2004529167A5
Authority
JP
Japan
Prior art keywords
buffer
cyclodextrin
drug
histidine
prednisolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002586950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529167A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/013701 external-priority patent/WO2002089815A2/en
Publication of JP2004529167A publication Critical patent/JP2004529167A/ja
Publication of JP2004529167A5 publication Critical patent/JP2004529167A5/ja
Pending legal-status Critical Current

Links

JP2002586950A 2001-05-07 2002-04-29 殺菌および可溶化ステロイド組成物 Pending JP2004529167A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28933701P 2001-05-07 2001-05-07
PCT/US2002/013701 WO2002089815A2 (en) 2001-05-07 2002-04-29 Disinfecting and solubilizing steroid compositions

Publications (2)

Publication Number Publication Date
JP2004529167A JP2004529167A (ja) 2004-09-24
JP2004529167A5 true JP2004529167A5 (enExample) 2005-12-22

Family

ID=23111093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002586950A Pending JP2004529167A (ja) 2001-05-07 2002-04-29 殺菌および可溶化ステロイド組成物

Country Status (9)

Country Link
US (1) US20020198174A1 (enExample)
EP (2) EP1702619A2 (enExample)
JP (1) JP2004529167A (enExample)
AT (1) ATE337010T1 (enExample)
AU (1) AU2002308544B2 (enExample)
CA (1) CA2446528A1 (enExample)
DE (1) DE60214157T2 (enExample)
ES (1) ES2269763T3 (enExample)
WO (1) WO2002089815A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
CA2342797A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
WO2004069280A1 (en) * 2003-02-06 2004-08-19 Cipla Ltd Pharmaceutical inclusion complexes containing a steroid and optionally an antibacterial agent
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
AU2011235943B2 (en) * 2003-12-31 2014-06-26 Cydex Pharmaceuticals, Inc Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
JP2007517069A (ja) * 2003-12-31 2007-06-28 サイデックス・インコーポレイテッド スルホアルキルエーテルγ−シクロデキストリンおよびコルチコステロイドを含む吸入製剤
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US7892483B2 (en) 2004-03-12 2011-02-22 Cipla Limited Sterilization process
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US6969706B1 (en) * 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
US8128954B2 (en) 2004-06-07 2012-03-06 California Institute Of Technology Biodegradable drug-polymer delivery system
US20060006361A1 (en) * 2004-07-08 2006-01-12 Joseph Callerame Clathrate of chlorine dioxide
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070197487A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an increased lung deposition
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
AR059574A1 (es) * 2006-02-14 2008-04-16 Wyeth Corp Formulaciones farmaceuticas acuosas de ligandos selectivos er-beta
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US20080097335A1 (en) 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
CN101795565A (zh) * 2007-06-28 2010-08-04 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US7999741B2 (en) * 2007-12-04 2011-08-16 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene using precision location
US8545554B2 (en) 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
CA2862076C (en) 2012-01-23 2020-04-21 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CN113616661A (zh) 2016-03-08 2021-11-09 萨奇治疗股份有限公司 神经活性类固醇、其组合物及用途
IL266964B2 (en) 2016-11-29 2024-06-01 Oculis SA Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
TW202114697A (zh) 2019-07-01 2021-04-16 瑞士商歐庫利斯公司 用於穩定包括藥物的水性組成物之pH值的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
DE3612538A1 (de) * 1986-04-14 1987-10-15 Dispersa Ag Stabilisierung von quecksilberhaltigen konservierungsmitteln in augentropfen
US4822819A (en) * 1986-11-07 1989-04-18 Alcon Laboratories, Inc. Use of trimoprostil and derivatives in glaucoma therapy
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5504113A (en) * 1994-03-02 1996-04-02 Allergan, Inc. Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug
AU3609795A (en) * 1994-10-10 1996-05-02 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
JP3170619B2 (ja) * 1995-04-20 2001-05-28 参天製薬株式会社 有機アミンを配合したプラノプロフェン点眼液
US5744154A (en) * 1995-09-06 1998-04-28 Laboratoire Chauvin S.A. Ready-to-use indomethacin-based eye lotion
JP3883739B2 (ja) * 1998-05-22 2007-02-21 株式会社メニコン コンタクトレンズ用殺菌液
WO2000018316A2 (en) * 1998-09-25 2000-04-06 Alcon Laboratories, Inc. Sustained release, and comfortable ophthalmic composition and method for ocular therapy

Similar Documents

Publication Publication Date Title
JP2004529167A5 (enExample)
US11337919B2 (en) Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
JP2008515556A5 (enExample)
BR0314340A (pt) Formulações que compreendem granulados solúveis em água
WO2004032862A3 (en) Cyclodextrin-based materials, compositions and uses related thereto
CA2526310A1 (en) Lipophilic fluid cleaning compositions capable of delivering scent
DE69918296D1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
JP2007302683A5 (enExample)
DE602004031444D1 (de) Herstellung von monatin und monatinvorstufen
NO332405B1 (no) Forbindelse av 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling, deres anvendelse til fremstilling av farmasoytiske midler for behandling av inflammatorisk sykdom og farmasoytisk preparat omfattende forbindelsen.
SE0102438D0 (sv) New compounds
WO2007067890A3 (en) Method of dust abatement
JP2003506416A5 (enExample)
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
DK0967176T3 (da) Agglomerater på basis af aktivt kul, deres fremstillingsmåde og anvendelse som adsorptionsmidler
WO2003097587A3 (en) Gelling agents
DE60022230D1 (de) Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv
JP2008512527A5 (enExample)
WO2005001242A3 (en) Composition and method for diversion agents for acid stimulation of subterranean formations
JP2006505678A5 (enExample)
JP2022009021A5 (enExample)
JP2004534739A5 (enExample)
MD1419G2 (ro) Complecşi de incluziune pe bază de SIN-1A şi ciclodextrină, compoziţii farmaceutice şi truse pe baza lor, procedeu de preparare a complecşilor de incluziune şi metodă de tratament
DE60118742D1 (de) Arzneistoffabgabesystem für wasser schwerlösliche arzneimittel
ATE374172T1 (de) Hexensäurederivate, verfahren zu deren herstellung, pharmazeutische zusammensetzungen, die diese enthalten, und therapeutische anwendungen davon